Added to YB: 2026-03-17
Pitch date: 2026-03-13
CDIO [bearish]
Cardio Diagnostics Holdings, Inc.
+13.93%
current return
Author Info
Fugazi Research exposes inflated valuations built on illusion — not substance. We dissect the narratives, trace the incentives, and reveal who’s really cashing in. In a market full of noise, we show what’s real behind the fugazi. Sign up for the newsletter.
Company Info
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
Market Cap
$5.1M
Pitch Price
$2.80
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.12
P/E
-0.75
EV/Sales
47.08
Sector
Biotechnology
Category
N/A
$CDIO: A Heartbreaking Diagnosis for Investors
CDIO (short): De-SPAC w/ $901 lifetime rev at merger; now $11.3k TTM rev (-63% YoY) vs $5M net loss (-44,500% margin). CEO paid $300k (26x TTM rev). Raised $15M equity vs $65k cumulative sales. Float +476% since 2022; 1:30 reverse split to avoid delisting. $5.9M ATM capacity vs $9M mkt cap = massive dilution risk. Opaque ownership: founder shares transferred day-1 post-SPAC, zero SEC disclosure since. Sponsor Intrater tied to 2 failed SPACs down 97-99%. Zero commercial traction; equity sales = true biz model.
Read full article (12 min)